Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patient Exclusion Analysis Coming From FDA; Changes In Trial Recruitment Could Follow

This article was originally published in The Pink Sheet Daily

Executive Summary

Subjects with psychiatric conditions are often excluded from trials, an agency study finds, which “doesn’t seem a good thing” to Bob Temple.

You may also be interested in...



FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle

Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.

FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle

Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.

FDA To Be More Vigilant About Proposed Clinical Trial Exclusions

FDA’s Bob Temple says “document” being drafted will instruct reviewers to pay more attention during sponsor meetings and eliminate unnecessary exclusions from protocols.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS074486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel